Literature DB >> 32713225

Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics.

Arzu Ataseven1, Selami Aykut Temiz1, Güllü Eren2, İlkay Özer1, Recep Dursun1.   

Abstract

BACKGROUND: Biological agent treatments represent a relatively new field and their effects on routine laboratory parameters are not fully known as there has been little research in the area. In our study, we aimed to evaluate the differences between the two main biological treatment groups and their effects on routine laboratory parameters.
METHODS: Patients were enrolled when they had received treatment for more than six months with biological treatments between January 2013 and April 2020. The available data on routine laboratory parameters were collected by routine blood tests before the treatment, at three months, and at the final evaluation.
RESULTS: When the changes in routine laboratory parameters were evaluated by treatment, it was found that the NLR and CRP values decreased statistically significantly in the anti-TNF group compared to the IL inhibitor group. In addition, strong suppression of these inflammation parameters means strong suppression of the immune system response. In addition, AST, ALT, and creatinine values were found to be statistically significantly higher in the anti-TNF group compared to the IL inhibitor group.
CONCLUSIONS: In our study, anti-TNF treatments are shown to be more effective in reducing inflammation parameters while IL antagonists are safer in terms of biochemical parameters.

Entities:  

Keywords:  IL-12-23 inhibition; IL-17 inhibition; Psoriasis; TNF inhibition; biologics

Mesh:

Substances:

Year:  2020        PMID: 32713225     DOI: 10.1080/09546634.2020.1801975

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

Review 1.  Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.

Authors:  Ana Ion; Alexandra Maria Dorobanțu; Liliana Gabriela Popa; Mara Mădălina Mihai; Olguța Anca Orzan
Journal:  Biology (Basel)       Date:  2022-05-25

2.  Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.

Authors:  Matteo Megna; Luca Potestio; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Psoriasis (Auckl)       Date:  2022-07-14

3.  Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report.

Authors:  Abdullah Muqrin Al Muqrin; Abdulaziz A Alghamdi; Ziad M AlShaalan
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-10-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.